Potentially inappropriate benzodiazepine use in Australian adults: A population-based study (2014-2017).
benzodiazepines
drug misuse
drug utilisation
long-term use
pharmacoepidemiology
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
13
08
2019
revised:
17
02
2020
accepted:
08
04
2020
pubmed:
12
5
2020
medline:
15
7
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Inappropriate benzodiazepine use continues to cause substantial morbidity and mortality globally. We aimed to characterise the initiation of new benzodiazepine treatment episodes in Australia and identify correlates of potentially inappropriate benzodiazepine use. We conducted a population-based cohort study using dispensing claims from a 10% sample of Pharmaceutical Benefit Scheme eligible Australians (2014-2017). Our cohort comprised adults initiating a new benzodiazepine treatment; we defined potentially inappropriate use as ≥3 benzodiazepine dispensing over any continuous 90-day period in the year following initiation. We examined characteristics associated with potentially inappropriate benzodiazepine use using multivariable logistic regression. People initiating a new benzodiazepine treatment episode (n = 276 765) were more frequently female (59.1%) and <65 years of age (73.6%). In the 90 days prior to initiating benzodiazepine, people were commonly dispensed antidepressants (26.5%), opioid analgesics (17.6%) and antipsychotics (4.7%). In the first year after initiation, 20 938 (9.5%) people experienced 'potentially inappropriate use'. Having a greater initial quantity of benzodiazepine dispensed [odds ratio (OR), 1.10; 95% confidence interval (CI) 1.08-1.12 per 10 defined daily doses increase], dispensing of antipsychotics (OR 3.00, 95% CI 2.86-3.15) and >5 unique medicines (OR 2.54, 95% CI 2.44-2.64; vs. ≤5 unique medicines) in the 90 days prior to initiation were associated with potentially inappropriate benzodiazepine use. Approximately, 1 in 10 people who initiated benzodiazepines were using it beyond the guideline recommended period. We identified factors at the time of initiation associated with potentially inappropriate use; clinicians should consider these before prescribing benzodiazepines and initiate conversations about alternative therapy when necessary.
Substances chimiques
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-582Subventions
Organisme : Australian Government Department of Industry, Innovation and Science Cooperative Research Centre Project Grant
ID : CRC-P-439
Pays : International
Organisme : Australian National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines and Ageing
ID : 1060407
Pays : International
Organisme : NHMRC Early Career Fellowship
ID : 1158763 to A.L.S
Pays : International
Organisme : National Health and Medical Research Council
Pays : International
Informations de copyright
© 2020 Australasian Professional Society on Alcohol and other Drugs.
Références
Kurko TAT, Saastamoinen LK, Tähkäpää S et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry 2015;30:1037-47.
Australian Bureau of Statistics. Drug induced deaths in Australia: A changing story. Canberra, Australia: Australian Bureau of Statistics, 2016 Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2016~Main%20Features~Drug%20Induced%20Deaths%20in%20Australia~6.
Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health 2016;106:686-8.
Billioti de Gage S, Moride Y, Ducruet T et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ 2014;349:g5205.
Brett J, Wylie CE, Raubenheimer J, Isbister GK, Buckley NA. The relative lethal toxicity of pharmaceutical and illicit substances: a 16-year study of the greater Newcastle hunter area, Australia. Br J Clin Pharmacol 2019;85:2098-107.
Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60.
Lader M. Benzodiazepines revisited-will we ever learn? Addiction 2011;106:2086-109.
eTG complete (Australian Therapeutics Guidelines). Psychotropics. Melbourne (VIC): Therapeutic Guidelines Ltd, 2017.
Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd., 2018:2018.
Kurko T, Saastamoinen LK, Tuulio-Henriksson A et al. Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014. Pharmacoepidemiol Drug Saf 2018;27:674-82.
The Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part B: Benzodiazepines 2018. Available at: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/prescribing-drugs-of-dependence/prescribing-drugs-of-dependence-part-b. (accessed 3 August, 2018).
Brett J, Karanges EA, Daniels B et al. Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry 2017;51:990-9.
Brett J, Maust DT, Bouck Z et al. Benzodiazepine use in older adults in the United States, Ontario, and Australia from 2010 to 2016. J Am Geriatr Soc 2018;66:1180-5.
Wingård L, Taipale H, Reutfors J et al. Initiation and long-term use of benzodiazepines and Z-drugs in bipolar disorder. Bipolar Disord 2018;20:634-46.
van Hulten R, Teeuw KB, Bakker A, Leufkens HG. Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up. Eur J Clin Pharmacol 2003;58:689-94.
Saarelainen L, Tolppanen A-M, Koponen M et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. Int J Geriatr Psychiatry 2018;33:583-90.
Vozoris NT, Fischer HD, Wang X et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging 2013;30:183-92.
Gerlach LB, Maust DT, Leong SH, Mavandadi S, Oslin DW. Factors associated with long-term benzodiazepine use among older adults. JAMA Intern Med 2018;178:1560-2.
Manthey L, Giltay EJ, van Veen T, Neven AK, Zitman FG, Penninx BWJH. Determinants of initiated and continued benzodiazepine use in The Netherlands study of depression and anxiety. J Clin Psychopharmacol 2011;31:774-9.
Tvete IF, Bjørner T, Skomedal T. A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam. Br J Gen Pract 2016;66:e241-7.
Tvete IF, Bjørner T, Skomedal T. New benzodiazepine and Z-hypnotic users and disability pension: an eight-year nationwide observational follow-up study. Scand J Prim Health Care 2017;35:240-6.
Mellish L, Karanges EA, Litchfield MJ et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes 2015;8:634.
Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS. Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J 2014;44:57-64.
Australian Bureau of Statistics. 2019]. Quarterly Population Estimates. Available at: http://stat.data.abs.gov.au/Index.aspx?DataSetCode=ERP_QUARTERLY (accessed August 2019).
Cadogan CA, Ryan C, Cahir C, Bradley CP, Bennett K. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol 2018;84:1354-63.
Ladapo JA, Larochelle MR, Chen A et al. Physician prescribing of opioids to patients at increased risk of overdose from benzodiazepine use in the United States. JAMA Psychiat 2018;75:623-30.
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356:j760.
Bushnell GA, Stürmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiat 2017;74:747-55.
Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003;54:1395-401.
Seal KH, Shi Y, Cohen G et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA 2012;307:940-7.
Brett J, Daniels B, Karanges EA et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol 2017;83:2581-8.
Bachhuber MA, Maughan BC, Mitra N, Feingold J, Starrels JL. Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: early evidence from 11 United States metropolitan areas. Int J Drug Policy 2016;28:120-3.
Schaffer AL, Buckley NA, Cairns R, Pearson S-A. Interrupted time series analysis of the effect of rescheduling alprazolam in Australia: taking control of prescription drug use. JAMA Intern Med 2016;176:1223-5.
Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf 2010;19:280-8.